# Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination

> **NCT07133802** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Changchun BCHT Biotechnology Co.** · enrollment: 6680 (estimated)

## Conditions studied

- Prevention of Influenza

## Interventions

- **BIOLOGICAL:** Placebo Group
- **BIOLOGICAL:** Test Group

## Key facts

- **NCT ID:** NCT07133802
- **Lead sponsor:** Changchun BCHT Biotechnology Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2026-03
- **Final completion:** 2026-07
- **Target enrollment:** 6680 (ESTIMATED)
- **Last updated:** 2025-08-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07133802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07133802, "Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07133802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*